Bilthoven (the Netherlands) and Dresden (Germany) – InteRNA Technologies B.V. and Cenix BioScience GmbH announce signing of a Research Agreement comprising functional screens in human cell lines using InteRNA’s proprietary library of miRNAs.
Cenix will apply InteRNA’s unique lentiviral-based miRNA overexpression library in high throughput screening assays in combination with high content, multi-parametric phenotypic analyses to identify the biological role of individual miRNAs and novel therapeutic targets in the area of cancer.
“We are very much pleased to work in collaboration with Cenix to further advance our drug discovery efforts to identify miRNA regulated targets for cancer therapy. Cenix’ unique expertise on small RNA-based high-throughput screening and phenotypic analyses will be instrumental in our discovery programs”, said Roel Schaapveld, Chief Operating Officer of InteRNA Technologies.
“We very much appreciate the confidence that our colleagues at InteRNA are showing by commissioning Cenix to contribute in such a substantial manner to their discovery programs” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “The planned work promises very exciting scientific and technological challenges that are clearly in line with the recent diversification of Cenix activities into the miRNA space, and which we look forward to tackling together”.